BIOCYTOGEN
15.9.2022 14:03:42 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.
Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.
“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”
FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.
“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”
About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.
About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005284/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Reports Q2 2026 Results, with Continued Accelerated Growth in its Specialty Ingredients & Solutions Business3.8.2026 12:03:00 CEST | Press release
SIS revenues (Specialty Ingredients & Solutions) grew 131% in Q2 to US$22 million.Group revenues for the quarter grew 16% to US$92.5 million.Adjusted EBITDA1 for the SIS grew by more than 3 times YoY to US$4.2 million, reflecting an adjusted EBITDA margin of 19.2%.The SIS business represented 24% of total revenues and 40% of adjusted EBITDA.Group’s adjusted net profit grew 4% to US$5.3 million.Cashflow from operating activities was strong, increasing to US$15.5 million. Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth, highlighted by the increasing contribution of our Specialized Ingredients Solutions (SIS) business. We are clearly seeing the results of the transformation we have been leading over the past year, with revenue from our Specialized Ingredients Solutions business more than doubling compared to the same period last year. The business now contributes approximately 40% of the Group's adjusted EBITDA. We
Historic French Luxury Leather Goods House Moreau Paris Sold to Leading Manufacturer3.8.2026 11:00:00 CEST | Press release
ASTEREN announces that the Paris Commercial Court has approved the acquisition of Moreau Paris, one of France’s most prestigious luxury leather goods houses, by Cardinal Invest, owner of the French luxury manufacturer Groupe Lécuyer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803029803/en/ Paris flagship rue du Faubourg Saint-Honoré (source: Moreau Paris) The transaction concludes a competitive international sale process conducted under the supervision of the Paris Commercial Court and marks the beginning of a new chapter for one of the last independent historic Paris monogram houses. Led by judicial liquidator Pablo Castanon at ASTEREN, with Richard Morgan Advisory as financial advisor, the process launched in early June attracted substantial interest from trade and financial investors worldwide. The Court order signed on 29 July lays the foundations for renewed investment, international expansion and long-term indus
Kioxia to Showcase CXL™ Compatible Memory Expansion Module KIOXIA XL1 Series for AI Workloads3.8.2026 10:22:00 CEST | Press release
Kioxia Corporation, a world leader in memory solutions, today announced that it will exhibit the KIOXIA XL1 series, a Compute Express Link™ (CXL™) compatible memory expansion module, at the Kioxia booth at FMS: the Future of Memory and Storage, taking place August 4 - 6 in Santa Clara, CA. The product features KIOXIA XL-FLASH™, a low-latency and high-performance flash memory technology that enables flash memory, traditionally used for storage applications, to also be utilized as a memory expansion solution. In addition, it is being designed and developed to support the growing volume of memory-intensive AI applications. Evaluation samples are scheduled to be shipped to industry ecosystem collaborators in August 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803920975/en/ CXL™ Compatible Memory Expansion Module KIOXIA XL1 Series In recent years, the growing number of AI workloads has significantly increased memory de
Leading Data Centre Operator CEO Announced for Data Center World Europe Keynote3.8.2026 09:00:00 CEST | Press release
Powerhouse Conference Agenda Addresses Critical Infrastructure Challenges; Data Center World Europe Takes Place 13-14 October 2026 in Vienna Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, today announces Svein Alte Hagaseth, Founder and CEO, Heim Datacenter will deliver the opening keynote. A recognised industry leader, Svein spent a decade at Green Mountain in several leadership roles, including CEO, scaling the business from regional challenger to global leader. He is now Founder and CEO of Heim Datacenter, a Nordic platform developing scalable, sustainable infrastructure for hyperscale, high-performance computing. Bill Kleyman, Executive Chair, Data Center Programs, Data Center World/CEO and Co-Founder, Apolo will be joining the keynote as moderator. Data Center World Europe takes place 13-14 October 2026 at VIECON – Vienna
Energy Impact Partners Expands Nordic Investment Presence, Deepening Partnership with Nysnø Climate Investments3.8.2026 08:02:00 CEST | Press release
EIP reinforces commitment to Norway as a defining center for next-generation energy innovation Energy Impact Partners LP ("EIP"), a global investment firm with over $5 billion in assets under management, today announced an expanded commitment to the Nordic energy innovation ecosystem, building on its longstanding strategic partnership with Nysnø Climate Investments ("Nysnø"). The expansion reflects EIP's conviction that Norway and the broader Nordic region will be a defining source of next-generation energy companies. It also marks a deepening of the firm's institutional relationship with Nysnø, an investor in EIP's $1.36 billion flagship fund. Together, the two firms aim to strengthen connectivity between Nordic founders and EIP's global network spanning venture capital, private equity, and credit. "Norway is one of the most sophisticated and forward-looking energy markets in the world," said Matthias Dill, CEO & Managing Partner, Europe at EIP. "We believe many of the defining compan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom